DIA Global Annual Meeting – San Diego, CA (June 16-20th, 2024)
Come meet our team at DIA’s Global Annual Meeting June 16th – 20th in San Diego, CA. Steve Satek, Executive Vice President, Chicago, is participating in a panel on Monday on the impact of incorporating patient diversity tactics and resources early in the clinical trial planning and budgeting process.
The expert panel will address the critical issue of representation in clinical trials, and the evidence which shows that improving diversity in clinical trials requires early planning. They will present a cost analysis and case examples on the impact of incorporating patient diversity tactics and resources early. The goal is to equip decision makers with the tools they need to make informed decisions during the budget process to effectively plan and allocate resources towards patient diversity efforts.
This session will be one you do not want to miss! We hope to see you there!
Session Information:
Title: The Cost of Moving the Needle on Clinical Trial Representation: Strategies for Diversity Budget Planning and Resourcing
Track: Clinical Trials and Clinical Operations
Date and Time: Monday, June 17 (2:15-3:15 PM)
Session Overview:
Evidence shows that improving diversity in clinical trials requires early planning. The session presents a cost analysis and case examples from an expert panel on the impact of incorporating patient diversity tactics and resources early in the clinical trial planning process.
Session Abstract:
“Don’t tell me what you value, show me your budget, and I’ll tell you what you value.”
Representation in clinical trials has become a hot topic over the past few years, with an increase in clinical trial sponsor commitments and initiatives to help combat a health equity issue that has plagued clinical research for decades.
Despite new U.S. regulations that are requiring sponsors to develop and execute diversity action plans for many of their trials, innovative tactics designed to increase patient diversity are often the first line items to be cut from budgets during the study planning process. There are several potential reasons for this, including the perceptions that there is no clear return on investment or that the tactics cost more than the current study budget can handle. The reality is the evidence shows that improving diversity in clinical trials requires budget investments, and early on in study planning. Furthermore, the FDA requires sponsors to develop and execute diversity action plans to enforce compliance and may impose penalties for non-compliance. Understanding the consequences of regulatory non-compliance is essential for clinical trial sponsors, as it directly influences the decision-making regarding budget allocation for diversity initiatives.
Through the unique vantage points of experts from across the clinical trial ecosystem, the session will help quantify the resources and revenue needed to successfully improve representation in clinical trials. Attendees will be presented with unique case examples that show how budgeting for diversity upfront can help deliver diversity plan goals.